Pfizer Inc. (NYSE:PFE) Shares Acquired by Argent Advisors Inc.

Argent Advisors Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 91,137 shares of the biopharmaceutical company’s stock after buying an additional 10,584 shares during the quarter. Pfizer comprises approximately 1.0% of Argent Advisors Inc.’s portfolio, making the stock its 20th biggest holding. Argent Advisors Inc.’s holdings in Pfizer were worth $2,550,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. HighMark Wealth Management LLC lifted its position in Pfizer by 124.5% during the second quarter. HighMark Wealth Management LLC now owns 4,045 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 2,243 shares during the period. Callahan Advisors LLC lifted its position in Pfizer by 32.3% during the second quarter. Callahan Advisors LLC now owns 385,377 shares of the biopharmaceutical company’s stock worth $10,783,000 after buying an additional 94,140 shares during the period. Investors Asset Management of Georgia Inc. GA ADV lifted its position in Pfizer by 11.5% during the second quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 79,735 shares of the biopharmaceutical company’s stock worth $2,231,000 after buying an additional 8,220 shares during the period. TrueMark Investments LLC lifted its position in Pfizer by 171.3% during the second quarter. TrueMark Investments LLC now owns 120,138 shares of the biopharmaceutical company’s stock worth $3,361,000 after buying an additional 75,856 shares during the period. Finally, Nations Financial Group Inc. IA ADV lifted its position in Pfizer by 75.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 80,627 shares of the biopharmaceutical company’s stock worth $2,256,000 after buying an additional 34,670 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.0 %

Shares of PFE stock traded up $0.28 during trading hours on Friday, reaching $29.00. The company had a trading volume of 37,119,970 shares, compared to its average volume of 38,496,418. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $36.29. The company has a market capitalization of $164.33 billion, a P/E ratio of -483.33, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. The stock’s fifty day simple moving average is $28.97 and its 200 day simple moving average is $28.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the firm earned $0.67 EPS. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.79%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Wells Fargo & Company raised their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Barclays raised their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Morgan Stanley raised their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.